search
Back to results

Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS

Primary Purpose

Infertility, Polycystic Ovarian Syndrome

Status
Unknown status
Phase
Phase 4
Locations
Egypt
Study Type
Interventional
Intervention
Clomiphene citrate and Prednisolone
Clomiphene citrate and folic acid
Sponsored by
Mahmoud Thabet
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility focused on measuring PCOS, Clomiphene citrate resistant, Prednisolone

Eligibility Criteria

20 Years - 35 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Infertile lean women with PCOS as defined by the Rotterdam criteria.
  • CC resistance (defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles).

Exclusion Criteria:

  • Age < 20 or > 35 years.
  • Body mass index (BMI) < 18.5 kg/m2 or > 25 kg/m2.
  • Presence of any infertility factor other than anovulatory PCOS.
  • Previous history of ovarian surgery or surgical removal of one ovary.
  • Previous exposure to cytotoxic drugs or pelvic irradiation.
  • Oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months.
  • Metabolic or hormonal abnormalities

Sites / Locations

  • Obstetrics and Gynecology Department in Mansoura University HospitalRecruiting
  • Private practice settingsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Clomiphene citrate-Prednisolone group

Clomiphene citrate-placebo group

Arm Description

Women will receive clomiphene citrate and prednisolone

Women will receive clomiphene citrate and folic acid 0.5mg (placebo)

Outcomes

Primary Outcome Measures

Ovulation rate
Number of ovulatory cycles divided by the number of stimulation cycles

Secondary Outcome Measures

Number of ovarian follicles ≥ 18 mm on day of HCG administration
Number of ovarian follicles ≥ 18 mm by TVS on day of HCG administration
Endometrial thickness on day of HCG administration
Endometrial thickness by TVS on day of HCG administration
Clinical pregnancy rate
Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 6-8 weeks gestational age) divided by the number of women

Full Information

First Posted
January 18, 2015
Last Updated
January 4, 2019
Sponsor
Mahmoud Thabet
search

1. Study Identification

Unique Protocol Identification Number
NCT02344888
Brief Title
Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS
Official Title
Adding Prednisolone During Ovulation Induction With Clomiphene Citrate in Lean Women With Clomiphene Citrate Resistant Polycystic Ovarian Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Unknown status
Study Start Date
February 2015 (undefined)
Primary Completion Date
January 2019 (Actual)
Study Completion Date
January 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Mahmoud Thabet

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effect of concomitant administration of prednisolone during use of clomiphene citrate (CC) for induction of ovulation in infertile lean women having CC resistant polycystic ovarian syndrome (PCOS).
Detailed Description
Women will be randomly divided into two groups; CC-Prednisolone group and CC-placebo group. Women in the CC-Prednisolone group will receive CC (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone tablet (5 mg/day for 10 consecutive days from day 2 of the cycle). Women in the CC-placebo group will receive CC alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid tablet (0.5 mg/day for 10 consecutive days from day 2 of the cycle). Transvaginal sonography (TVS) scan will be performed regularly for monitoring of follicular growth (folliculometry); starting from day 10 of the stimulation cycle and repeated every 2-3 days. When there will be at least one follicle ≥ 18 mm in diameter, final oocyte maturation will be induced by intramuscular administration of 10000 IU of human chorionic gonadotropin (HCG) and timed intercourse will be advised. If there will be no follicle ≥ 12 mm by day 16 of the cycle, monitoring of follicular growth will be discontinued and the cycle will be presumed to be anovulatory. Ovulation will be documented by TVS scan one week after triggering of oocyte maturation and will be confirmed by assessing the mid-luteal serum progesterone level. Each woman will be subjected to ovarian stimulation for a maximum of 3 consecutive cycles except if she gets pregnant in the first or second cycle

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility, Polycystic Ovarian Syndrome
Keywords
PCOS, Clomiphene citrate resistant, Prednisolone

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Clomiphene citrate-Prednisolone group
Arm Type
Active Comparator
Arm Description
Women will receive clomiphene citrate and prednisolone
Arm Title
Clomiphene citrate-placebo group
Arm Type
Active Comparator
Arm Description
Women will receive clomiphene citrate and folic acid 0.5mg (placebo)
Intervention Type
Drug
Intervention Name(s)
Clomiphene citrate and Prednisolone
Other Intervention Name(s)
Clomid and Hostacortin-H
Intervention Description
Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of the cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of the cycle)
Intervention Type
Drug
Intervention Name(s)
Clomiphene citrate and folic acid
Other Intervention Name(s)
Clomid and folic acid
Intervention Description
Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of the cycle) and folic acid (0.5 mg/day for 10 consecutive days from day 2 of the cycle)
Primary Outcome Measure Information:
Title
Ovulation rate
Description
Number of ovulatory cycles divided by the number of stimulation cycles
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Number of ovarian follicles ≥ 18 mm on day of HCG administration
Description
Number of ovarian follicles ≥ 18 mm by TVS on day of HCG administration
Time Frame
3 months
Title
Endometrial thickness on day of HCG administration
Description
Endometrial thickness by TVS on day of HCG administration
Time Frame
3 months
Title
Clinical pregnancy rate
Description
Number of clinical pregnancies (defined as presence of at least one intrauterine gestational sac with fetal pole and cardiac activity on TVS scan at 6-8 weeks gestational age) divided by the number of women
Time Frame
6-8 weeks gestational age

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Infertile lean women with PCOS as defined by the Rotterdam criteria. CC resistance (defined as failure of ovulation after receiving 150 mg/day of CC for 5 consecutive days per cycle, for at least 3 consecutive cycles). Exclusion Criteria: Age < 20 or > 35 years. Body mass index (BMI) < 18.5 kg/m2 or > 25 kg/m2. Presence of any infertility factor other than anovulatory PCOS. Previous history of ovarian surgery or surgical removal of one ovary. Previous exposure to cytotoxic drugs or pelvic irradiation. Oral hypoglycemic or hormonal therapy either currently or in the preceding 3 months. Metabolic or hormonal abnormalities
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mahmoud M Abdelrazik, Dr
Phone
+201005548881
Email
dr_mahmoudhosam@yahoo.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mahmoud M Abdelrazik, Dr
Organizational Affiliation
Mansoura University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mahmoud Thabet, D
Organizational Affiliation
Mansoura University
Official's Role
Study Director
Facility Information:
Facility Name
Obstetrics and Gynecology Department in Mansoura University Hospital
City
Mansourah
State/Province
Dakahlia
ZIP/Postal Code
35111
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mahmoud M Abdelrazik, Dr
Phone
+201005548881
Email
dr_mahmoudhosam@yahoo.com
Facility Name
Private practice settings
City
Mansourah
State/Province
Dakahlia
Country
Egypt
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Adding Prednisolone During Ovulation Induction With CC in Lean Women With CC Resistant PCOS

We'll reach out to this number within 24 hrs